Phosphodiesterases 4 (PDE4) act as proinflammatory enzymes via degradation of cAMP, while PDE4 inhibitors play an anti-inflammatory role in vitro and in vivo. In particular, apremilast has been recently approved for the treatment of psoriasis and psoriatic arthritis. However, little is known on the expression pattern of PDE4 in psoriasis. We report that PDE4B and PDE4D mRNA are overexpressed in peripheral blood mononuclear cells (PBMC) from psoriasis, as compared to normal controls, while apremilast reduces PBMC production of a number of pro-inflammatory cytokines and increases the levels of anti-inflammatory mediators. PDE4 expression is up-regulated in psoriatic dermis, as compared to normal skin, with particular regard to fibroblasts. This is confirmed in vitro, where both dermal fibroblasts (DF) and, to a greater extent, myofibroblasts (DM) express all PDE4 isoforms at the mRNA and protein level.
However, the expression patterns of PDE4 isoforms have not been studied in blood or skin of patients with inflammatory disease such as psoriasis.
PDE4 inhibitors are a well-characterized class of pharmaceutical agents, with a broad range of anti-inflammatory activities in vitro, and in in vivo preclinical models of asthma, lung neutrophilia, arthritis, inflammatory bowel disease, multiple sclerosis, osteoporosis and other conditions (Videla S,. J Pharmacol Exp Ther. 
qRT-PCR
Quantitative RT-PCR was performed to confirm overexpression of PDE4B and PDE4D isoforms in PBMC from patients with psoriasis. PBMC samples (n=20 each from psoriasis patients and healthy donors) were cultured for 24 hours in 5% autologous serum. RNA was isolated, converted to cDNA and analyzed by qRT-PCR, and a comparison of PBMC from psoriasis patients versus normal controls was conducted by t-test.
Multiplexed Bead-Based Immunoassay
PBMCs from psoriasis patients (n=10) were obtained after informed consent by Conversant Healthcare Systems (Huntsville, Alabama). The diagnosis of psoriasis was made on a case report form by the responsible physician in a network of medical clinics, research clinics, hospitals, and outpatient medical facilities. PBMCs were thawed (minimum viability was 80%), plated at 2x10 
Skin Immunohistochemistry (IHC)
Immunohistochemistry was performed on dermis samples from healthy controls and from patients with psoriasis, atopic dermatitis (AD), and discoid lupus Biosciences, Inc. (Seattle, WA) using the primary antibodies as described above. The principal detection system consisted of a Vector anti-rabbit secondary (BA-1000) and a
Vector ABC-AP kit (AK-5000) with a Vector Red substrate kit (SK-5100).
Isolation of primary fibroblasts and cell treatment
Normal human dermal fibroblasts (DF) were isolated from healthy skin biopsies obtained from waste materials from Operating Room. Patient consent for experiments was not required because Italian laws considers human tissue left over from surgery as discarded material. Briefly, DF were obtained by explant culture and grown in Dulbecco's modified Eagle's medium (DMEM) containing 5% fetal bovine serum (FBS).
Transforming growth factor-β 1 (TGF-β 1 ) (1 ng/mL, Sigma, St. Louis, Missouri) was added in fibroblast secondary culture for six days to promote differentiation into myofibroblasts (DM). The myofibroblast phenotype was checked by immunostaining in situ of α-smooth muscle actin (α-SMA).
For cell treatment, Apremilast was diluited in DMSO 10mM and used at the final concentration of 10μM in culture medium without serum. DF and MF were plated in DMEM with FBS. 48h after seeding, Apremilast or DMSO were added to DMEM for 2 hours and, after that, diluent, 100 ng/ml human recombinant NGF (Sigma-Aldrich), 1ng/ml TGF-β 1 (Sigma-Aldrich), 40μM β-amyloid 25-35 (Bachem, Bubendorf, Switzerland) were added to medium. Cells were monitored and used for further experiments 48 hours later.
Immunofluorescence (IF) in situ
DF were plated on chamber slides and, 48 hours after seeding, were treated with TGF- Micrographs were taken on a Confocal Scanning Laser Microscopy (Leica TCS SP2) (Leica, Exton, PA, USA).
Co-Immunoprecipitation
DF and DM were cultured until pre-confluent condition. Cells were harvested with lysis buffer pH 7.5 (150 nM NaCl, 15 mM MgCl, 1 mM EGTA, 50 mM Hepes, 10%
glycerol, 1% Triton) containing protease inhibitors. Monoclonal antibody CD271
(Upstate, Lake Placid, New York), was bound to sepharose beads for 1 h at 4 ºC under rotation. Thereafter, pre-cleared lysates were conjugated to sepharose beads-antibody complex or, as control, to sepharose beads alone or to antibody alone, overnight at 4 ºC under rotation. Immunocomplexes were washed with binding buffer (50 mM Tris-HCl, pH 7.5; 100 mM NaCl; 2 mM MgCl 2 , 1 mM DTT, 0.5% Triton X-100, 0.5% bovine serum albumin) six times. Samples were eluted with 2x Laemnli sample buffer for 5 minutes at 90 ºC and Western blotting for PDE4A, B, C and D was performed as described below.
Western Blotting
Total proteins (20 μg) or immunocomplexes were analyzed under non-reducing conditions on 7.5% polyacrylamide gels. To obtaine total proteins, cells were washed with phosphate-buffered saline (PBS) and lysed on ice, in lysis buffer pH 7.5 (150 nM NaCl, 15 mM MgCl, 1 mM EGTA, 50 mM Hepes, 10% glycerol, 1% Triton) containing protease inhibitors. Briefly, after the electrophoretic separation, total proteins or immunocomplexes were blotted onto nitrocellulose membranes. The blots were blocked for 2 hours in blocking buffer (PBS buffer, pH 7.4 with 0.2% Tween 20 and 5% nonfat milk) and incubated with rabbit polyclonal anti-human PDE4A antibody (1:1000, Proteintech group), rabbit polyclonal anti-human PDE4B antibody (1:300, Santa Cruz Biotechnology), rabbit polyclonal anti-human PDE4C antibody (1:300, Santa Cruz Biotechnology), rabbit polyclonal anti-human PDE4D antibody (1:300, Santa Cruz Biotechnology) or mouse monoclonal a-SMA (1:3000, Sigma-Aldrich) or mouse monoclonal anti-β-actin (1:1000; Sigma) overnight at 4 ºC. Then membranes were washed in TBS/Tween 20, incubated with peroxidase-conjugated goat anti-mouse or goat anti-rabbit or anti-mouse (1:3000, Biorad, Hercules, CA) antibodies for 45 min at room temperature. Finally, membranes were washed and developed using the ECL chemiluminescent detection system (Amersham Biosciences UK Limited, Little Chalfont Buckinghamshire, England). The band intensity was quantitatively determined using ImageJ software (Wayne Rasband, National Institute of Mental Health, Bethesda, MD, USA), and protein levels' intensity was normalized to β-actin expression.
MTT Assay
DF and DM were plated in a 96-well tissue culture plate (5000 cells/well). 48 hours after plating, cells were treated as described above with apremilast or DMSO for 2 hours, then treated with diluent (control), NGF (100 ng/mL), NT3 (100 ng/mL), or β-amyloid (40 
Propidium Iodide (PI) staining
At 48 hours after cell seeding, DF and DM were pretreated with DMSO or apremilast as described above, then diluent (control) or 40 µM β-amyloid were added. After 48 hours, cells were trypsinized and resuspended (5x10 5 cells) in 1 mL hypotonic fluorochrome solution: 50 mg/mL PI containing 0.1% sodium citrate and 0.5% TrytonX-100 (Sigma).
After 15 minutes, cells were analyzed using an Epics XL flow cytometer (Coulter Electornics Inc., Hialeah, FL). Apoptosis was detected by evaluating the fluorescence of hypodiploid cells counted in subG1 region.
TUNEL Assay
DF and DM after treatment were fixed in situ in paraformaldehyde (4% in PBS) and air- 
Migration Assay
A total of 20x10 4 DF were plated on 12-well tissue culture plates. 48 hours after seeding, cells were pretreated with DMSO or apremilast for 2 hours as described above, then cells were treated with 5 mg/mL mitomycin C for 1 hr 30 min. Subsequently, the cells were washed three times in serum-free medium and a line for each well was drawn along the cell monolayer with a sterile plastic tip. Plates were washed twice with serum-free medium to remove all detached cells and incubated in medium with BSA 0.1% with 1 ng/mL TGF-β 1 , 100 ng/mL human recombinant NGF in presence of DMSO or apremilast. Cells were monitored at 24 and 48 hours from stimulation. The result of each experiment was expressed as the mean of migrated cells from three different areas. The final results are expressed as the mean ± SD of three different experiments.
cAMP ELISA
At 48 hours after cell seeding, DF and DM were pretreated with DMSO or apremilast as described above, then diluent, 100 ng/mL human recombinant NGF (Sigma-Aldrich), or 40 μM β-amyloid (Bachem) were added to the culture medium.
48 hours later, supernatants were collected, particulates were removed by centrifugation and stored at -20 ºC. cAMP quantitation was performed by a competitive enzyme immunoassay (R&D Systems cAMP immunoassay, R&D Systems, Minneapolis, MN) according to manufacturer instructions. The sample concentration was determined by absorbance at 540 nm against a standard curve. cAMP levels are given in pmol/mL of cell lysate and results are expressed as mean ± SEM of triplicate from three different experiments.
RESULTS

Gene expression analysis of PDE4 isoforms in PBMC
We first wanted to analyze gene expression of PDE4 isoforms (A, B, C, and D)
in PBMC from healthy donors and from patients with 7 different immune-mediated or inflammatory diseases: psoriasis, rheumatoid arthritis (RA), idiopathic pulmonary fibrosis (IPF), sarcoidosis, scleroderma, Crohn's disease, and systemic lupus erythematosus (SLE). PDE4B and PDE4D isoforms were increased at the mRNA level in PBMC from psoriasis patients relative to normal controls ( Figure B and D, p<0.05 ).
PDE4D was also increased versus normal controls in PBMC from patients with SLE
( Figure 1D , p<0.05). PDE4C mRNA was preferentially overexpressed in PBMC from patients with Crohn's disease versus normal controls ( Figure 1C) , while PDE4A mRNA expression levels were similar across PBMC from normal controls and patients with the various immune/inflammatory diseases ( Figure 1A) . To confirm the overexpression of PDE4B and PDE4D mRNA in PBMC from patients with psoriasis relative to normal controls, quantitative RT-PCR was performed using 20 samples each from psoriasis patients and healthy donors. Mean relative gene expression in PBMC from psoriasis patients was 5.4-fold higher for PDE4B, and 2.2-fold higher for PDE4D (p<0.0001 for both vs normal control), compared with 1.1-fold for PDE4A (p=NS) ( Figure 1E ). There were no significant correlations between PDE4A, PDE4B, or PDE4D gene expression in the psoriatic PBMC with PASI, BSA, or sPGA scores (data not shown).
Effect of apremilast on the production of inflammatory mediators by PBMC from patients with psoriasis
Given the high PDE4 expression in psoriasis, we investigated the effect of apremilast on cytokines produced by PBMC from psoriatic patients. Psoriasis patient PBMC donors (n=10) included 5 females and 5 males ranging in age from 26 to 42 years, with PASI scores ≤26 and ≤33% body surface area affected. Two patients also had a diagnosis of psoriatic arthritis. Changes in production of various cytokines and chemokines upon stimulation of PBMCs from these psoriasis patients with LPS, staphylococcal enterotoxin A and B, TNF-α/IL-1β, or anti-IgM are shown in Figure 2A .
Addition of 1 μM apremilast had the greatest effect on psoriatic PBMC cultures stimulated via TLR4 (ie, LPS stimulation), with 13 of the 25 analytes significantly affected versus LPS control ( Figure 2B) . Specifically, apremilast caused significant inhibition of LPS-induced TNF-α, IL-12/IL-23p40, IFN-γ, IP-10, MCP-1, MCP-3, MIP-1β, IL-1α, IL-1β, and GM-CSF production, and increased IL-10, G-CSF, and VEGF production. In psoriatic PBMC stimulated with anti-IgM to ligate the B cell receptor, apremilast decreased production of the cytokines TNF-α, IL-1α, and IFN-γ, and the chemokines MCP-1, MCP-3, MIP-1β, and IP-10, and increased IL-10, G-CSF, VEGF, and IL-6. In psoriatic PBMC cultures stimulated via the T-cell receptor or TNF and IL-1 receptor, apremilast had far fewer effects (data not shown).
PDE4 expression in inflammatory skin infiltrates
Psoriasis is an immune-mediated disease characterized by a dense dermal infiltrate extravasating from the blood stream. Immuno-inflammatory infiltrate in turn is responsible for the epidermal alterations. For this reason, we focused on the expression of PDE4 proteins, that are markedly elevated in PBMC from psoriatic patients, in the dermal infiltrate from lesional psoriatic skin. Also dermis from healthy subjects, atopic dermatitis (AD), and discoid lupus erythematosus (DLE) was evaluated. In general, PDE4 staining was higher in diseased vs. normal skin when measured by ImageJ software ( Figure 3B ). PDE4A was expressed at the cytoplasmic level in a few dermal cells, most likely fibroblasts, in healthy skin, while it was markedly increased in fibroblasts from psoriasis, AD, and discoid lupus erythematous (DLE). PDE4B was slightly expressed by dermal cells both in healthy and psoriatic skin. In AD, PDE4B
staining was somewhat more expressed in the dermis of AD skin as compared to controls. In this context, dermal fibroblasts appeared intensely positive. In dermis from DLE skin, PDE4B staining was markedly increased, as compared to healthy controls, dermal fibroblasts being strongly positive. PDE4C was considerably more expressed in the dermis from psoriatic or AD sections than in skin from healthy controls. In DLE, PDE4C staining intensity was higher than in AD or psoriasis, fibroblasts being intensely stained. PDE4D expression was markedly higher in dermal infiltrate (fibroblasts) from psoriasis, AD or DLE than in healthy skin. Finally, CD271 appeared more expressed in fibroblasts from psoriasis and AD than in healthy skin or DLE ( Figure 3A) .
In order to better characterize PDE4 protein expression in psoriatic skin, a more detailed analysis was performed in the dermis. PDE4A, B, and D staining was evaluated and interpreted by a pathologist, and each antibody was evaluated for the presence of specific signal and level of background. Staining intensity was recorded on a 0-4 scale (0=negative, 1=blush, 2=faint, 3=moderate, 4=strong) ( Table 1) . Overall, lymphocytes present in the psoriatic skin were moderately to strongly positive for PDE4A and PDE4B, and faintly positive for PDE4D. Pilosebaceous units, sweat glands, sweat ducts, hair follicles, and arrector pili smooth muscle were positive. Fibroblasts were positive, and endothelium stained strongly for PDE4A, PDE4B, and PDE4D.
Specifically, PDE4A expression showed increased intensity and prevalence of staining in nearly all cell types in psoriatic vs. normal samples, although neutrophils within microabscesses were exceptionally negative. PDE4B staining in psoriatic samples was very prominent in vessels in the superficial dermis, and positively stained inflammatory cells were more abundant than in normal samples. PDE4D staining in psoriatic samples was present in fibroblasts and endothelium. Lymphocytes showed frequent staining in both normal and psoriatic skin samples, but were far more prevalent in the psoriasis samples. The endothelium of psoriatic skin showed a relatively large increase in PDE4 expression compared to normal skin, with PDE4A and PDE4D displaying strong staining in psoriatic endothelium, but only faint staining in normal endothelium. In fibroblasts, PDE4A expression was moderate to strong in psoriatic skin, but absent in normal skin. PDE4D expression was moderate in psoriatic fibroblasts, but faint in normal fibroblasts. In overall terms of staining intensity, the endothelium and fibroblasts showed the largest consistent increase in PDE4 expression in psoriatic vs. normal skin.
PDE4 isoforms co-immunoprecipitate with CD271 in fibroblasts
Due to the large increase in PDE4 staining observed in psoriatic fibroblasts, this isoforms (PDE4A,B,C, and D) co-localize with CD271 in dermal fibroblasts. We showed that PDE4 isoforms co-immunoprecipitate with CD271 in DM ( Figure 4E) . However, in DF, CD271 formed only weak complexes with PDE4A and PDE4B and no complex with PDE4C or PDE4D.
PDE4-CD271 complex function in fibroblasts in vitro
To evaluate the effect of the PDE4-CD271 complex on proliferation and apoptosis in fibroblasts, DF and DM were pretreated with apremilast or DMSO for 2 hours and then treated with NGF, NT3, β-amyloid, or diluent. Treatment with β-amyloid significantly decreased the percentage of proliferative cells for both DF and DM cultures compared with diluent control. In DM, the addition of apremilast significantly inhibited the effect of β-amyloid (p<0.05 vs DMSO), while apremilast had no effect versus DMSO in DF (Figure 5A, B) . Similarly, the addition of apremilast significantly reduced the induction of apoptosis by β-amyloid treatment in DM (p<0.05 vs DMSO, Figures 5D, F) but not in DF (Figures 5C E) .
It has been shown previously that neurotrophins mediate DF migration, and that neurotrophins as well as TGF-β 1 induce DF to differentiate into DM by expressing α-SMA.{Palazzo, 2012 3572 /id} We therefore analyzed whether the addition of apremilast could affect DF migration and α-SMA expression. Apremilast inhibited DF migration induced by both NGF and TGF-β 1 treatment (Figure 6A, B) . Similarly, apremilast inhibited the up-regulation of α-SMA expression induced by NGF and TGF-β 1 , especially 6 days after treatment ( Figure 6C ).
cAMP ELISA was performed to evaluate if activation of the CD271-PDE4 complex leads to cAMP degradation. In this analysis, neither apremilast alone nor apremilast in combination with NGF exerted any significant effect on release of cAMP by either DF or DM ( Figure 7A ). On the other hand, in DM, Apremilast reduced cAMP degradation induced by treatment with β-amyloid ( Figure 7B Because of the higher PDE4 gene expression observed in psoriasis patient blood, a careful analysis of the skin was conducted. PDE4 protein expression is higher in the skin of patients psoriasis, atopic dermatitis, and discoid lupus, as compared to normal skin. In a detailed IHC analysis of PDE4 protein expression in psoriatic skin, the endothelium and fibroblasts, in particular, shows increased expression of PDE4A and PDE4D, as compared to normal skin. Little had previously been known about the expression of PDE4 isoforms in human dermal fibroblasts. Selige and co---workers showed that primary normal human lung fibroblasts (NHLF) express PDE4A, B, and D, while PDE4C is only barely detected (Selige J, J Cell Physiol.2011 , 226:1970 . In the present study, we found that all PDE4 isoforms are expressed Taken together, these results indicate that PDE4 play an important role in psoriasis. In addition, the study reveals that the complex PDE4/CD271 could be important in modulating fibroblasts functions. and DM were pretreated with apremilast (10 μM) or DMSO for 2 hours, then NGF or beta-amyloid were added to medium as described in Materials and Methods.
Supernatants of DF (A) or DM (B) were collected 48 hours later and cAMP levels were evaluated by ELISA analysis. Data represent the mean ± SE of triplicate determinations.
